{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:29:45Z","timestamp":1756384185461,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y20211021"],"award-info":[{"award-number":["Y20211021"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2019ZYY04"],"award-info":[{"award-number":["2019ZYY04"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.taap.2024.116934","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T01:10:35Z","timestamp":1713921035000},"page":"116934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Differential inhibition of sildenafil and macitentan on saxagliptin metabolism"],"prefix":"10.1016","volume":"486","author":[{"given":"Ge-xin","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Administration, U.S.F.a.D","key":"10.1016\/j.taap.2024.116934_bb0005"},{"key":"10.1016\/j.taap.2024.116934_bb0010","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/jm050261p","article-title":"Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Augeri","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2024.116934_bb0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/675994","article-title":"Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension","volume":"4","author":"Benson","year":"2014","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.taap.2024.116934_bb0020","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidi nyl]-N '-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist","volume":"55","author":"Bolli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2024.116934_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40262-016-0421-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of Saxagliptin, a dipeptidyl Peptidase-4 inhibitor","volume":"56","author":"Boulton","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2024.116934_bb0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","article-title":"Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans","volume":"42","author":"Bruderer","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.taap.2024.116934_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/14740338.2016.1159675","article-title":"Saxagliptin for the treatment of diabetes - a focus on safety","volume":"15","author":"Cernea","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.taap.2024.116934_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ilar.38.1.41","article-title":"Special report: the 1996 guide for the care and use of laboratory animals","volume":"38","author":"Clark","year":"1997","journal-title":"ILAR J."},{"key":"10.1016\/j.taap.2024.116934_bb0045","first-page":"120","article-title":"Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies","volume":"20","author":"Davidson","year":"2014","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.taap.2024.116934_bb0050","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.taap.2024.116934_bb0055","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40265-014-0266-9","article-title":"Macitentan: a review of its use in patients with pulmonary arterial hypertension","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2024.116934_bb0060","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2024.116934_bb0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0300-595X(82)80011-X","article-title":"The effects of diabetes on male sexual function","volume":"11","author":"Fairburn","year":"1982","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.taap.2024.116934_bb0070","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/bmc.2720","article-title":"Development of a rapid UPLC-MS\/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study","volume":"26","author":"Gao","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.taap.2024.116934_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/878670","article-title":"Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives","volume":"2014","author":"Gareri","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.taap.2024.116934_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109559","article-title":"Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro","volume":"345","author":"Han","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.taap.2024.116934_bb0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1463-1326.2011.01417.x","article-title":"Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes","volume":"13","author":"Henry","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.taap.2024.116934_bb0090","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1111\/bcp.13757","article-title":"Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided","volume":"84","author":"Huppertz","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.116934_bb0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jcph.639","article-title":"Lack of pharmacokinetic interactions between Macitentan and a combined Oral contraceptive in healthy female subjects","volume":"56","author":"Hurst","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.116934_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cphy.c190018","article-title":"Pulmonary circulation in obesity, diabetes, and metabolic syndrome","volume":"10","author":"Khaing","year":"2019","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.taap.2024.116934_bb0105","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/jphp.13153","article-title":"Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro","volume":"71","author":"Li","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.taap.2024.116934_bb0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/fcp.12693","article-title":"Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro","volume":"36","author":"Liu","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.116934_bb0115","first-page":"242","article-title":"Echocardiographic follow-up to right ventricular modifications in secondary pulmonary hypertension to diabetes in rats","volume":"43","author":"L\u00f3pez","year":"2020","journal-title":"Clin. Exp."},{"key":"10.1016\/j.taap.2024.116934_bb0120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00228-022-03397-w","article-title":"Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers","volume":"78","author":"Mansour","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2024.116934_bb0125","first-page":"305","article-title":"Prevalence and type of sexual dysfunctions in diabetic males: a standardized clinical approach","volume":"18","author":"Miccoli","year":"1987","journal-title":"J. Med."},{"key":"10.1016\/j.taap.2024.116934_bb0130","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.taap.2024.116934_bb0135","first-page":"227","article-title":"The endothelin system in pulmonary arterial hypertension","author":"Nazzareno","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2024.116934_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107773","article-title":"Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: the Fremantle diabetes study phase I","volume":"35","author":"Nundlall","year":"2021","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.taap.2024.116934_bb0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40265-013-0156-6","article-title":"Macitentan: first global approval","volume":"74","author":"Patel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2024.116934_bb0150","first-page":"13","article-title":"Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole","volume":"3","author":"Patel","year":"2011","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.taap.2024.116934_bb0155","first-page":"8","article-title":"The PyMOL molecular graphics system","volume":"1","author":"Schr\u00f6dinger","year":"2015","journal-title":"Version"},{"key":"10.1016\/j.taap.2024.116934_bb0160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2024.116934_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijstd.IJSTD_99_17","article-title":"A meta-analysis on efficacy and tolerability of sildenafil for erectile dysfunction in patients with diabetes mellitus","volume":"39","author":"Shah","year":"2018","journal-title":"Indian J. Sex Transm. Dis. AIDS"},{"key":"10.1016\/j.taap.2024.116934_bb0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40261-014-0207-0","article-title":"Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects","volume":"34","author":"Sidharta","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.taap.2024.116934_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09059180.00004812","article-title":"Pathways in pulmonary arterial hypertension: the future is here","volume":"21","author":"Sitbon","year":"2012","journal-title":"European Respiratory Rev. An Official J. European Resp. Soc."},{"key":"10.1016\/j.taap.2024.116934_bb0180","first-page":"1003","article-title":"SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"59","author":"Spinar","year":"2013","journal-title":"Vnitr. Lek."},{"issue":"Suppl. 3","key":"10.1016\/j.taap.2024.116934_bb0185","article-title":"Pharmacologic treatment of erectile dysfunction","volume":"4","author":"Steers","year":"2002","journal-title":"Rev. Urol."},{"key":"10.1016\/j.taap.2024.116934_bb0190","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1124\/dmd.112.045450","article-title":"Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition\/induction profile of saxagliptin in human","volume":"40","author":"Su","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2024.116934_bb0195","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.2147\/DDDT.S268796","article-title":"Functional measurement of CYP2C9 and CYP3A4 allelic polymorphism on sildenafil metabolism","volume":"14","author":"Tang","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.taap.2024.116934_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040921","article-title":"The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension","volume":"11","author":"Vrigkou","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.taap.2024.116934_bb0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2013.01.010","article-title":"Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro","volume":"701","author":"Weiss","year":"2013","journal-title":"Eur. J. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:43:40Z","timestamp":1715953420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"alternative-id":["S0041008X24001327"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.116934","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential inhibition of sildenafil and macitentan on saxagliptin metabolism","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.116934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116934"}}